CLOUD
RENAULT GROUP FINALISES A STRATEGIC PARTNERSHIP WITH WANDERCRAFT, A LEADER IN NEXT GENERATION ROBOTICS
Renault Group and Wandercraft announce the closing of a minority investment by Renault Group in Wandercraft, one of the first companies to develop, manufacture and market medical self-balancing exoskeletons. Building on its strong expertise in powerful and reliable exoskeletons, Wandercraft has developed an advanced platform for uses such as manufacturing. Renault Group invests together with Wandercraft’ s existing shareholders and new investors.
Through a commercial partnership agreement, Renault Group and Wandercraft aim to ensure the development of Calvin, a family of next generation robots, firstly for industrial uses. Calvin will allow Renault Group to relieve its workers from painful and non-ergonomics tasks, while reducing production time and thus gaining on productivity.
At a later stage, this partnership will also include the industrialisation of robots and exoskeletons by Renault Group in order to reduce costs through design-to-cost and scaling – two disciplines in which the automotive industry is well recognised.
This will help Wandercraft to bring its new exoskeleton, Eve, on the market and open new business opportunities in robotics.
“ This partnership with Wandercraft is a forward-looking move. It will allow us to accelerate on automation and to develop robots for our specific auto industrial use, giving us the opportunity to concentrate our people on more valueadding tasks and alleviate operators from painful and nonergonomics duties,” said Thierry Charvet, Chief Industry and Quality Officer of Renault Group. �
www. intelligenthealth. tech 53